Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan;57(1):20-26.
doi: 10.1016/j.resinv.2018.09.001. Epub 2018 Oct 4.

Resistance to molecularly targeted therapy in non-small-cell lung cancer

Tetsuhiko Asao  1 , Fumiyuki Takahashi  2 , Kazuhisa Takahashi  2
Affiliations
Review

Resistance to molecularly targeted therapy in non-small-cell lung cancer

Tetsuhiko Asao et al. Respir Investig. 2019 Jan.

Abstract

The discovery of oncogenic driver gene mutations, including epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion, ROS proto-oncogene 1 (ROS1) fusion, and ret proto-oncogene (RET) fusion, has led to the development of molecularly targeted therapy for non-small-cell lung cancer (NSCLC). This therapy has changed the standard of care for NSCLC. Despite the dramatic response to molecularly targeted therapy, almost all patients ultimately develop resistance to the drugs. To understand the mechanisms of resistance to molecularly targeted agents, it is essential to understand the molecular pathways of NSCLC. Here, we review the mechanisms of resistance to molecularly targeted therapy and discuss strategies to overcome drug resistance.

Keywords: ALK; Acquired resistance; EGFR; Lung cancer; Molecularly targeted therapy.

PubMed Disclaimer

MeSH terms